(Q44004637)

English

Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma

scientific article published on 12 September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 November 2017

Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma (English)

1 reference

Europe PubMed Central

28 November 2017

1 reference

ChEBI release 2020-05-28

metastatic melanoma

1 reference

based on heuristic

inferred from title

Alexander J. Lazar

2

1 reference

Europe PubMed Central

28 November 2017

author name string

Sapna P Patel

1

1 reference

Europe PubMed Central

28 November 2017

Nicholas E Papadopoulos

3

1 reference

Europe PubMed Central

28 November 2017

Ping Liu

4

1 reference

Europe PubMed Central

28 November 2017

Jeffrey R Infante

5

1 reference

Europe PubMed Central

28 November 2017

Michelle R Glass

6

1 reference

Europe PubMed Central

28 November 2017

Carol S Vaughn

7

1 reference

Europe PubMed Central

28 November 2017

Patricia M LoRusso

8

1 reference

Europe PubMed Central

28 November 2017

Roger B Cohen

9

1 reference

Europe PubMed Central

28 November 2017

Michael A Davies

10

1 reference

Europe PubMed Central

28 November 2017

Kevin B Kim

11

1 reference

Europe PubMed Central

28 November 2017

language of work or name

0 references

publication date

12 September 2012

1 reference

Europe PubMed Central

28 November 2017

1 reference

Europe PubMed Central

28 November 2017

119

1 reference

Europe PubMed Central

28 November 2017

799-805

1 reference

Europe PubMed Central

28 November 2017

4

1 reference

Europe PubMed Central

28 November 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Genetic alterations in signaling pathways in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27790

1 reference

Europe PubMed Central

28 November 2017

1 reference

Europe PubMed Central

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44004637&oldid=2105566599"